Financial Performance - The company reported its audited consolidated results for the year ended December 31, 2023, in accordance with GEM listing rules[3]. - The company's operating revenue for the year reached approximately RMB 289.1 million, a decrease of about 22.5% compared to the previous year[20]. - The company reported a loss of approximately RMB 19.2 million for the year, compared to a profit of RMB 14.2 million in the previous year[20]. - Gross profit for the year was approximately RMB 127.4 million, down about 12.9% from RMB 146.3 million in the previous year, with a gross margin of approximately 44.1%, an increase from 39.2% in the previous year[39]. - Research and development costs totaled approximately RMB 35.8 million, an increase of about 33.3% from RMB 26.9 million in the previous year, mainly due to increased R&D expenses for flow cytometers and related reagents[42]. - The company reported a net debt increase of approximately RMB 15.56 million compared to the previous year, primarily due to operating losses leading to reduced cash flow from operating activities[53]. - As of December 31, 2023, the company's cash and bank balances were RMB 63.41 million, down from RMB 77.35 million in 2022[52]. - The company's net debt to equity ratio increased to 34% in 2023 from 27% in 2022, indicating a higher leverage position[52]. - The total employee cost for the year was approximately RMB 99 million, an increase from RMB 90 million in 2022, reflecting the company's investment in human resources[58]. - The company recorded retained earnings of approximately RMB 30.88 million as of December 31, 2023[157]. - The distributable reserves available to shareholders were approximately RMB 14.43 million as of December 31, 2023, compared to RMB 9.52 million as of December 31, 2022[157]. Corporate Governance - The board of directors does not recommend the distribution of any dividends for the fiscal year ending December 31, 2023[24]. - The board of directors held a total of seven meetings during the fiscal year 2023, with an average attendance rate of 75%[80]. - The board is responsible for overseeing the group's management, business strategy, and financial matters, including major acquisitions and capital transactions[68]. - The company has not established a corporate governance committee, delegating governance functions to the board[69]. - The board has implemented mechanisms to ensure independent opinions and inputs, including enhancing the recruitment process for independent non-executive directors[74]. - The company has confirmed that all independent non-executive directors meet the independence criteria as per the GEM Listing Rules[76]. - The board's composition includes members with expertise in technology, medicine, and economics, ensuring representation of shareholders' interests[76]. - The board reviewed and monitored compliance with legal and regulatory requirements during the reporting period[75]. - The company has established a code of conduct and compliance manual for employees and directors[75]. - The board's meetings included discussions on corporate governance policies and the training of directors and senior management[75]. - The board of directors has established three committees: the Remuneration Committee, the Nomination Committee, and the Audit Committee to oversee specific areas of the company's affairs[88]. - The company has adopted a standard code of conduct for directors regarding securities trading, ensuring compliance with GEM Listing Rules[85]. - The company is committed to evaluating the performance of executive directors and reviewing the remuneration of all directors[92]. - The board's strategic oversight includes approving annual budgets and business plans, as well as assessing company performance[84]. - The board has adopted a diversity policy for board appointments, considering factors such as gender, age, cultural background, and professional experience[95]. - The nomination committee held two meetings during the reporting period, with all members attending at least one meeting[98]. - The company aims to achieve gender diversity on the board, targeting the appointment of at least one female director by December 31, 2024[101]. - The company has maintained compliance with all corporate governance codes, except for the internal audit function, which is currently not established due to the group's scale and operational structure[176]. Market and Industry Insights - The company acknowledges the potential market volatility risks associated with trading securities on GEM[4]. - The Chinese in vitro diagnostics (IVD) market is projected to grow from RMB 170 billion in 2022 to RMB 288.15 billion by 2030, with an expected market share increase to 33.2% globally[47]. - The IVD industry is undergoing significant changes, with opportunities and challenges arising in various segments, particularly in immunodiagnostics and molecular diagnostics[37]. - The IVD industry is expected to see increased market concentration and intensified competition, prompting companies to focus on quality improvement and cost reduction[48]. - The company is focused on enhancing its research and development capabilities to mitigate risks associated with technological obsolescence in the IVD industry[123]. - The company aims to enhance its core competitiveness and market position through strategic collaborations with industry leaders[28]. - The company is actively seeking strategic partnerships with industry leaders to explore new profit models and enhance its competitive edge[51]. - The company is positioned to capitalize on the growing demand for healthcare solutions, driven by advancements in technology and increasing healthcare needs[198]. Operational Developments - The report includes a comprehensive financial summary and management discussion and analysis[7]. - The company completed 100 Class II product and 10 Class III product registration changes during the reporting period[28]. - The company has developed nine new products, including the MTHFR (C677T) gene testing kit, which are currently undergoing registration[28]. - The company has established a performance evaluation system focused on project outcomes in its R&D center[26]. - The company is focusing on expanding its sales network and enhancing its marketing strategies to increase revenue[26]. - The company has made significant progress in the development of innovative diagnostic products, including immunofluorescence and molecular diagnostics[26]. - The company has two self-built comprehensive factories covering a total area of 37.17 acres, with the first factory primarily used for office, R&D, and biochemical reagent production, and the second for diagnostic reagent production[46]. - The increase in sales and distribution expenses to approximately RMB 59 million, up about 7.2% from RMB 55 million in the previous year, was mainly due to enhanced sales efforts[40]. - Administrative expenses rose to approximately RMB 51.5 million, an increase of about 15.1% from RMB 44.7 million in the previous year, primarily due to increased employee costs[41]. - The company aims to enhance its product planning and cost control strategies in response to the pressures from healthcare reforms and procurement policies affecting profit margins[34]. - The company is committed to maintaining high standards in clinical testing and diagnostics, supported by its experienced management team[197]. Risk Management and Compliance - The company emphasizes the importance of maintaining effective internal controls and risk management systems to protect shareholder interests[118]. - The company has established a comprehensive risk management system to identify and manage key operational risks[120]. - The company has implemented a quality management system based on ISO 9001:2008 and ISO 13485:2003, ensuring quality control throughout the production process[123]. - The board confirmed that there are no significant uncertainties regarding the company's ability to continue as a going concern as of December 31, 2023[114]. - The company has adopted an insider information disclosure policy to ensure compliance with confidentiality regulations and obligations[127]. - A whistleblowing policy has been implemented to provide a confidential reporting channel for employees and external parties regarding potential misconduct or illegal activities[128]. - The company has a robust anti-corruption policy in place, prohibiting all forms of corruption and regularly reviewing the policy to align with legal requirements and industry best practices[132]. - The company has not identified any significant omissions or defects in its internal audits during the reporting period, confirming the effectiveness of its risk management measures[126]. - In 2024, the company plans to revise relevant systems and build a more effective internal audit structure to enhance risk management in daily operations[126]. Shareholder Communication and Engagement - The company is committed to maintaining effective communication with shareholders and ensuring compliance with the GEM Listing Rules[110]. - The company ensures that shareholder opinions are communicated to the board and has established various channels for this purpose[142]. - The company has not engaged in any purchase, redemption, or sale of its listed securities during the year[60]. - The company has not established any indemnity provisions for directors or connected companies during the year[182]. - The company plans to propose the reappointment of Ernst & Young as its auditor at the upcoming annual general meeting[185]. Leadership and Management - The chairman and president positions are held by Mr. Wu Lebin and Mr. Chen Peng, respectively, with clearly defined responsibilities[84]. - The company has appointed several experienced directors, including Mr. Chen Zhengyong and Mr. Yang Peng, who bring over 40 years and 20 years of experience in the medical and financial sectors respectively[193][196]. - The company has a strong board with members holding advanced degrees and significant experience in medical technology and management, enhancing its strategic direction[197][200]. - The board includes independent directors with notable academic and professional achievements, ensuring diverse perspectives in decision-making[200]. - The company is committed to maintaining transparency and open communication with shareholders and investors, utilizing various channels to provide timely and accurate information[133].

Financial Performance - For the three months ended September 30, 2023, the company reported revenue of RMB 71,418,000, a decrease of 30.8% compared to RMB 103,223,000 for the same period in 2022[14] - The gross profit for the third quarter of 2023 was RMB 35,217,000, down 23.1% from RMB 45,757,000 in the third quarter of 2022[14] - The operating loss for the third quarter of 2023 was RMB 6,255,000, compared to an operating profit of RMB 12,472,000 in the same quarter of the previous year[14] - The net loss attributable to the owners of the parent company for the third quarter of 2023 was RMB 569,000, compared to a profit of RMB 10,691,000 in the third quarter of 2022[14] - The company reported a net loss of RMB 10,698,000 for the nine months ended September 30, 2023, compared to a profit of RMB 17,377,000 for the same period in 2022[14] - The total revenue for the nine months ended September 30, 2023, was RMB 210,564,000, a decrease of 23.6% from RMB 275,659,000 in the same period of 2022[14] - The company’s total comprehensive loss for the nine months ended September 30, 2023, was RMB 10,662,000, compared to a profit of RMB 17,412,000 in the same period of 2022[15] - The company’s basic and diluted loss per share for the third quarter of 2023 was RMB 0.004, compared to earnings per share of RMB 0.074 in the same quarter of 2022[14] - The company reported a basic loss per share attributable to shareholders of RMB 4.86 for the three months ended September 30, 2023, compared to earnings of RMB 73.93 per share in the same period of 2022[26] Research and Development - Research and development expenses increased to RMB 9,724,000 in the third quarter of 2023, up 46.5% from RMB 6,646,000 in the same quarter of 2022[14] - The company continues to focus on expanding its research and development efforts despite the financial losses reported[14] - The company successfully obtained certification for over 50 core innovative products, including first and second-generation flow cytometers, from the Anhui Provincial Drug Administration, pushing them into clinical and research markets[31] - The company is focused on accelerating the transformation of scientific research achievements and improving its product pipeline through the establishment of a technology achievement transformation center[35] Market and Business Strategy - In the first three quarters of 2023, the company faced a gradual recovery in domestic medical institution visits and a steady growth in routine in vitro diagnostic testing demand[31] - The company aims to leverage the good opportunity of multi-province centralized procurement of biochemical reagents to further expand the market and improve cost efficiency[35] - The company is actively building a chain of precision medicine laboratories in cities like Beijing, Hefei, Chengdu, Jinan, and Nanchang to enhance research collaboration and academic promotion[31] - The company plans to strengthen its competitive advantage in the biochemical diagnostic market and increase market share through various initiatives[35] - The strategic cooperation system with institutions like the Chinese Academy of Sciences and major hospitals is expected to drive business development through integrated industry-university-research collaboration[35] - The company has received positive market feedback for its innovative equipment and reagent products in biochemistry, immunology, and early cancer screening[31] Ownership and Governance - The company reported a significant ownership structure, with key stakeholders holding approximately 36.01% each in Hong Kong Zhixin Investment Limited[1] - Yunnan Shengneng Investment Partnership holds a 43.0% stake, indicating a diversified ownership among multiple shareholders[2] - The company has established an audit committee to oversee financial reporting and internal control systems, ensuring compliance with GEM listing rules[3] - The company has adhered to all provisions of the Corporate Governance Code as per GEM listing rules, with minor exceptions noted[5] - The board has implemented measures to maintain risk management and internal control without establishing a dedicated internal audit department[6] - The company is committed to reviewing the necessity of an internal audit function periodically, based on operational needs[7] - The management team has engaged external consultants for internal reviews, enhancing oversight and compliance[8] - The company has not disclosed any conflicts of interest among its directors and management during the reporting period[9] - No significant changes in shareholder equity or related interests were reported as of September 30, 2023[10] Other Financial Information - The company’s financial expenses for the third quarter of 2023 were RMB 1,844,000, slightly up from RMB 1,843,000 in the same quarter of 2022[14] - The company did not declare an interim dividend for the nine months ended September 30, 2023, consistent with the previous year[30] - The company’s rental income for the three months ended September 30, 2023, was RMB 403,000, a decrease of 96.9% from RMB 13,345,000 in the same period of 2022[21] - The company’s deferred tax expense for the nine months ended September 30, 2023, was RMB 342,000, compared to RMB 2,000 in the same period of 2022[25] - The company’s total reserves as of September 30, 2023, amounted to RMB 199,892,000, down from RMB 210,451,000 as of September 30, 2022[29] - No purchases, sales, or redemptions of the company's listed securities were reported in the nine months ending September 30, 2023[4]

中 生 北 控 生 物科 技 股 份 有 限 公司 BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION （於中華人民共和國註冊成立的股份有限公司） 8247 （股份代號： ） 截至二零二三年九月三十日止三個月及九個月 第三季度業績公佈 GEM 香港聯合交易所有限公司（「聯交所」） 的特色 GEM 的定位，乃為相比起其他在聯交所上市的公司帶有較高投資風險的公司提供一個上市的 市場。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後方作 GEM GEM 出投資決定。 的較高風險及其他特色表示 較適合專業及其他老練投資者。 GEM GEM 由於 上市公司新興的性質所然，在 買賣的證券可能會較於聯交所主板買賣之證券 GEM 承受較大的市場波動風險，同時無法保證在 買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本公佈的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示概不就因本公佈全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 GEM GEM 本公佈乃遵照聯交所 《證券上市規則》（「 上市規則」） ...

Financial Performance - Biosino Bio-Technology reported a significant increase in revenue, achieving a total of RMB 200 million for the first half of 2023, representing a growth of 15% compared to the same period last year[19]. - The company's main business revenue for the six months ended June 30, 2023, was approximately RMB 139.1 million, a decrease of about 19.3% compared to RMB 172.4 million in the same period of 2022[32]. - Gross profit for the reporting period was approximately RMB 66.7 million, down about 4.8% from RMB 70.1 million in the same period last year, with a gross margin of approximately 48% compared to 41% in 2022[33]. - The company reported a loss of approximately RMB 8 million for the reporting period, compared to a profit of approximately RMB 4.7 million in the same period last year[37]. - The total comprehensive income for the six months ended June 30, 2023, was a loss of RMB 5,368,000, compared to a loss of RMB 7,956,000 for the same period in 2022[72]. - The operating profit for the six months ended June 30, 2023, was RMB 72,470,000, a decrease from RMB 102,381,000 in the same period of 2022, representing a decline of approximately 29.3%[89]. - The total tax expense for the six months ended June 30, 2023, was RMB 2,201,000, compared to RMB 2,440,000 in 2022, reflecting a decrease of approximately 9.8%[93]. - Basic earnings per share for the six months ended June 30, 2023, remained unchanged at RMB 0.50, consistent with the same period in 2022[94]. - The company did not declare an interim dividend for the six months ended June 30, 2023, which is the same as in 2022[98]. Research and Development - Research and development expenses increased by approximately 32.8% to RMB 16 million from RMB 12 million in the same period last year, with 49 Class II products and 3 Class III products completed for registration changes[36]. - The company is committed to developing new diagnostic technologies and products to meet the evolving needs of healthcare institutions[19]. - Future outlook indicates a strategic focus on expanding product lines and enhancing research and development efforts to maintain competitive advantage in the market[19]. - The company aims to leverage its strong ties with the Chinese Academy of Sciences to further enhance its research capabilities and product offerings[19]. Market Position and Strategy - The company expanded its distribution network, now covering over 600 distributors across more than 30 provinces and municipalities in China, enhancing its market reach[19]. - Biosino's diagnostic reagent products have gained widespread recognition, with the brand being awarded the "Beijing Famous Brand Product" title in 2002 and the "First Brand in User Satisfaction for Diagnostic Reagents in China" in 2005[19]. - The company plans to maintain quality advantages in traditional biochemical diagnostic products and increase market share through successful bidding in centralized procurement[40]. Financial Health and Assets - Biosino's financial health remains robust, with a solid balance sheet supporting ongoing investments in technology and market expansion initiatives[19]. - The net debt-to-equity ratio increased to 40% from 27% in the previous year, with total liabilities to total assets ratio remaining stable at 61%[45]. - As of June 30, 2023, the company had total non-current assets of RMB 208,403,000, slightly up from RMB 205,785,000 at the end of 2022[67]. - The company’s cash and cash equivalents decreased to RMB 54,777,000 as of June 30, 2023, down from RMB 77,349,000 at the end of 2022[67]. - The company’s inventory increased to RMB 65,012,000 as of June 30, 2023, compared to RMB 55,486,000 at the end of 2022[67]. - Total equity as of June 30, 2023, was RMB 226,151,000, down from RMB 234,107,000 as of December 31, 2022, indicating a decline of about 3.4%[69]. - The company reported a net cash decrease of RMB 22,572,000 for the six months ended June 30, 2023, compared to a decrease of RMB 8,347,000 in the same period of 2022[74]. Employee and Administrative Expenses - Total employee costs for the six months ended June 30, 2023, were approximately RMB 47,700,000, an increase of 15.8% from RMB 41,200,000 in the previous year[54]. - The increase in administrative expenses by approximately 20.6% to RMB 25.8 million was primarily due to rising employee costs[35]. - Sales and distribution expenses rose by approximately 7.9% to RMB 30.7 million, attributed to increased sales efforts[34]. - The total management compensation for the six months ended June 30, 2023, was RMB 3,145,000, a decrease from RMB 3,486,000 in 2022, reflecting a decline of about 9.8%[111]. Corporate Governance - The audit committee, consisting of three independent non-executive directors, has reviewed the unaudited condensed consolidated financial statements for the period[132]. - The company has complied with all corporate governance code provisions during the period, except for the internal audit function as per code provision D.2.5[133]. - The board has implemented measures to fulfill internal audit functions, including appointing external consultants for internal reviews[134]. - Following the resignation of an independent non-executive director, the company initially failed to meet the requirement of having at least three independent non-executive directors, which was rectified after a new appointment[137]. Shareholding and Securities - As of June 30, 2023, Mr. Wu Lebin holds 3,500,878 shares, representing 4.35% of the company's domestic shares and 2.42% of the total registered capital[116]. - Mr. Chen Peng holds 11,330,334 shares, accounting for 14.09% of the domestic shares and 7.83% of the total registered capital[116]. - Mr. Chen Zhengyong owns 10,000,000 shares, which is 12.43% of the domestic shares and 6.91% of the total registered capital[116]. - Beijing Pusai Asset Management Co., Ltd. directly holds 31,308,576 shares, representing 38.93% of the domestic shares and 21.64% of the total registered capital[118]. - Hong Kong Zhixin Investment Co., Ltd. holds 27,256,143 H shares, accounting for 42.40% of the H shares[118]. - Yunnan Shengneng Investment Partnership holds 10,939,314 domestic shares and 6,780,000 H shares, representing 13.60% and 10.55% of the respective categories[118]. - The company did not grant any rights to directors or supervisors to purchase shares or debt securities as of June 30, 2023[127]. - There were no purchases, sales, or redemptions of the company's listed securities by the company or its subsidiaries during the six months ending June 30, 2023[129]. - No directors, supervisors, or major shareholders held interests in any business that competes directly or indirectly with the company during the reporting period[128]. - The company has adopted the standards outlined in GEM Listing Rules 5.48 to 5.67 for the trading of securities by directors, with no known violations reported as of June 30, 2023[130].

中 生 北 控 生 物科 技 股 份 有 限 公司 BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION （於中華人民共和國註冊成立的股份有限公司） 8247 （股份代號： ） 中期業績公佈 截至二零二三年六月三十日止三個月及六個月 GEM 香港聯合交易所有限公司（「聯交所」） 的特色 GEM 的定位，乃為相比起其他在聯交所上市的公司帶有較高投資風險的公司提供一個上市的 市場。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後方作 GEM GEM 出投資決定。 的較高風險及其他特色表示 較適合專業及其他老練投資者。 GEM GEM 由於 上市公司新興的性質所然，在 買賣的證券可能會較於聯交所主板買賣之證券 GEM 承受較大的市場波動風險，同時無法保證在 買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本公佈的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示概不就因本公佈全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 GEM GEM 本公佈乃遵照 《證券上市規則》（「《 上市規則》」）的規定 ...

Financial Performance - The company's revenue for the first quarter of 2023 was RMB 71,103,000, a decrease of 19.7% compared to RMB 88,560,000 in the same period of 2022[15] - Gross profit for the first quarter was RMB 31,944,000, down 7.0% from RMB 34,688,000 year-over-year[15] - The operating loss for the quarter was RMB 3,157,000, compared to an operating profit of RMB 5,393,000 in the first quarter of 2022[15] - The net loss attributable to the owners of the parent company was RMB 5,132,000, compared to a profit of RMB 594,000 in the same quarter of the previous year[15] - Basic and diluted loss per share for the first quarter was RMB 0.04, compared to RMB 0.01 in the same period of 2022[15] - The total comprehensive loss for the period was RMB 6,173,000, compared to a total comprehensive income of RMB 2,132,000 in the first quarter of 2022[18] - The financial results indicate a significant decline in profitability, prompting a review of operational strategies moving forward[15] Research and Development - Research and development expenses increased to RMB 8,754,000, up 72.0% from RMB 5,074,000 in the first quarter of 2022[15] - The company is committed to enhancing its research and development capabilities to drive future growth[21] - The company has applied for a patent for a new detection reagent kit method that eliminates non-specific reactions in blood samples[37] Market and Sales - The company continues to focus on the production, sales, and distribution of in vitro diagnostic reagents[21] - Sales of in vitro diagnostic reagent products amounted to RMB 68,324 thousand, up from RMB 67,528 thousand year-on-year, indicating a growth of 1.2%[23] - The domestic in vitro diagnostic product market is characterized by large-scale automation and standardization, with biochemical diagnostic reagents and immunodiagnostic reagents accounting for over 50% of the total market demand[33] - The company is focusing on strengthening cooperation with distributors and end hospitals, while diversifying marketing models to expand sales channels[34] Corporate Governance - The company has established an Audit Committee to oversee financial reporting and internal control systems, consisting of three independent non-executive directors[55] - The company confirms that all directors complied with the standard code of conduct for securities trading during the reporting period[49] - No directors or supervisors have interests in any business that competes directly or indirectly with the company's operations[50] - The company has complied with all provisions of the Corporate Governance Code except for the internal audit function as per D.2.5[56] - The board has implemented measures to fulfill internal audit functions through external consultants due to the group's scale and operational structure[57] - The board will periodically review the necessity of establishing an internal audit function and may form an internal audit team if needed[57] Shareholding Structure - As of March 31, 2023, Mr. Chen Peng holds 11,330,334 shares, representing 14.09% of the domestic shares and 7.83% of the total registered capital[40] - Beijing Holdings Limited directly owns 27,256,143 H-shares, accounting for 42.40% of H-shares and 18.84% of the total registered capital[42] - Yunnan Shengneng Investment Partnership holds 10,939,314 domestic shares and 6,780,000 H-shares, representing 13.60% and 10.55% of their respective categories[42] - There are no significant changes in the shareholding structure of major shareholders as of March 31, 2023[48] Other Information - The group aims to optimize its investment structure and enhance asset operation efficiency, returning more resources to its core business[36] - The group has achieved significant results in promoting scientific research cooperation and technology exchange, continuously improving its industrial strategic layout[36] - The group reported a tax expense of RMB 1,012 thousand for the three months ended March 31, 2023, compared to RMB 1,091 thousand in the same period of 2022, reflecting a decrease of 7.2%[28] - The company did not recommend the distribution of an interim dividend for the three months ended March 31, 2023, consistent with the previous year[31] - No purchases, redemptions, or sales of the company's listed securities were made by the company or its subsidiaries during the reporting period[51] - The report does not provide specific user data or performance guidance for future quarters[44] - The company has not disclosed any new strategies or significant market expansions in the current report[44]

中 生 北 控 生 物科 技 股 份 有 限 公司 BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION （於中華人民共和國註冊成立的股份有限公司） 8247 （股份代號： ） 截至二零二三年三月三十一日止三個月 第一季度業績公佈 GEM 香港聯合交易所有限公司 的特色 GEM 的定位，乃為相比起其他在香港聯合交易所有限公司（「聯交所」）上市的公司帶有較高投 資風險的公司提供一個上市的市場。有意投資的人士應了解投資於該等公司的潛在風險，並 GEM GEM 應經過審慎周詳的考慮後方作出投資決定。 的較高風險及其他特色表示 較適合專 業及其他老練投資者。 GEM GEM 由於 上市公司新興的性質所然，在 買賣的證券可能會較於聯交所主板買賣之證券 GEM 承受較大的市場波動風險，同時無法保證在 買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本公佈的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示概不就因本公佈全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 GEM GEM 本公佈乃遵照聯交所 《證券上市規則》（「《 ...

Financial Performance - The company's operating revenue for the year reached approximately RMB 373 million, an increase of 7% compared to the previous year[19]. - The company's net profit for 2022 was RMB 14 million, a 3.5 times increase compared to the previous year, primarily due to profit increases from several subsidiaries[37]. - Gross profit for the reporting period was RMB 146 million, a 2% increase from last year, with a gross margin of 39% (down from 41% in 2021)[38]. - The group reported sales to the top five customers amounting to RMB 151 million, accounting for 40.5% of total revenue for the year[147]. - The largest customer contributed RMB 50 million, representing 13.4% of total revenue[147]. - The company recorded retained earnings of approximately RMB 16.447 million as of December 31, 2022[145]. - The company reported a comprehensive financial performance reflecting a fair view of its financial position as of December 31, 2022[197]. - The financial statements were prepared in accordance with Hong Kong Financial Reporting Standards, ensuring compliance with disclosure requirements[197]. - The financial performance for the year ended December 31, 2022, indicates a solid foundation for future growth[197]. Market Environment - The impact of the COVID-19 pandemic continued to affect both China and the global market, leading to intensified competition in the in vitro diagnostics industry[25]. - The company reported significant changes in the market environment due to the pandemic, affecting over 2,300 research and development enterprises and tens of thousands of operating businesses[25]. - The domestic IVD market is experiencing significant changes, with a focus on high-quality products that can replace imported brands becoming crucial for survival and development[31]. - The IVD market in China is expected to experience a recovery and stable growth phase, with hospital treatment numbers and routine testing projects anticipated to return to pre-pandemic levels by Q4 2023[45]. Strategic Focus - The company aims to enhance its market position through innovation and expansion strategies[25]. - The company is committed to maintaining sustainable business development amid financial considerations and capital requirements[24]. - The annual report highlights the importance of strategic adjustments in a rapidly changing market landscape[25]. - The company plans to enhance product competitiveness through process improvements and formula optimization, aiming to compensate for price reductions by increasing sales volume of existing key products[50]. - The company aims to explore new profit models by establishing strategic partnerships with leading players in the industry, focusing on flow cytometry and other future strategic priorities[50]. - The company will continue to consolidate and enhance its biochemical product business segment, improving product quality and expanding its revenue sources[50]. Governance and Compliance - The board of directors did not recommend the distribution of any dividends for the fiscal year ending December 31, 2022, consistent with the previous year[24]. - The board confirmed the accuracy and completeness of the financial report after thorough inquiries[5]. - The board has implemented measures to fulfill internal audit functions despite not establishing a dedicated internal audit department, ensuring adequate risk management and internal control[64]. - The board of directors consists of seven members, including three independent non-executive directors, ensuring compliance with governance standards[65]. - The company adheres to the GEM Listing Rules and has applied the principles of the Corporate Governance Code in its governance framework[63]. - The board has established three committees: the remuneration committee, the nomination committee, and the audit committee, to oversee specific areas of the company's affairs[85]. - The board has confirmed compliance with all relevant laws and regulations during the year[146]. Human Resources - As of December 31, 2022, the group employed a total of 531 full-time employees, an increase from 421 in 2021[58]. - The total employee cost for the year was approximately RMB 92 million, up from RMB 73 million in 2021, reflecting a significant increase in personnel expenses[58]. - The company emphasizes the importance of employee training, regularly providing training to enhance technical and product knowledge[58]. - The company continues to prioritize diversity in its recruitment policies for senior management positions[78]. - The company aims to have at least one female director as part of its diversity policy[97]. Risk Management - The company has established a comprehensive risk management system to identify and manage key operational risks, ensuring a safe and effective working environment[117]. - The company has implemented a three-line defense system for risk management, involving business departments, executive teams, and the board of directors[122]. - The company has established emergency mechanisms to mitigate risks from natural disasters and public health events, ensuring rapid response capabilities[120]. - The company conducts regular internal audits and risk assessments across various departments to ensure compliance and timely corrective actions[122]. Research and Development - Research and development costs totaled RMB 27 million, a 7% increase from RMB 25 million in 2021[40]. - The company is reforming its R&D project operation mechanism and establishing a performance evaluation system centered on projects[1]. - The company is focused on increasing R&D investment and attracting professional talent to enhance its scientific research capabilities and mitigate technology substitution risks[118]. - The company aims to leverage its research capabilities to innovate and introduce new products to the market[190]. Financial Management - The company is optimizing its investment structure and improving asset operation efficiency to return more resources to its core business[1]. - The net debt decreased by approximately RMB 54 million compared to the previous year, primarily due to cash flow from operating activities and non-controlling shareholder contributions[53]. - The capital structure showed a significant improvement, with the net debt-to-capital ratio decreasing from 59% in 2021 to 27% in 2022[52]. - The company has a strong management team with extensive experience in finance and biotechnology, enhancing its operational capabilities[190][191]. Shareholder Communication - The company is committed to maintaining transparency and open communication with shareholders, adhering to GEM listing rules for information disclosure[123]. - The company has a structured approach to shareholder communication, ensuring timely and clear information dissemination regarding strategies and financial performance[126].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不會就本公告全部或任何部分內容而產生或因 倚賴該等內容而引致之任何損失承擔任何責任。 中 生 北 控 生 物科 技 股 份 有 限 公司 BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION （於中華人民共和國註冊成立的股份有限公司） 8247 （股份代號： ） (I) 截至二零二二年十二月三十一日止年度的 全年業績公告；及 (II) 暫停辦理股份過戶登記手續 (I) 截至二零二二年十二月三十一日止年度的全年業績 中生北控生物科技股份有限公司（「本公司」）的董事（「董事」）會（「董事會」）謹此宣佈，本 公司及其附屬公司截至二零二二年十二月三十一日止年度的經審計業績。本公告列載本 GEM 公司二零二二年年報全文，乃符合香港聯合交易所有限公司（「聯交所」） 證券上市規 GEM 則（「 上市規則」）中有關年度業績初步公告附載的資料之相關要求。本公司的二零 二二年年報印刷本將寄發予本公司股東，並將於二零二三年三月三十一日刊載於香港交 (www.hkexn ...

Financial Performance - For the three months ended September 30, 2022, the company reported revenue of RMB 103,223,000, an increase of 18.5% compared to RMB 87,072,000 for the same period in 2021[12]. - The gross profit for the third quarter of 2022 was RMB 45,757,000, representing a gross margin of approximately 44.3%[12]. - The net profit for the three months ended September 30, 2022, was RMB 12,645,000, compared to RMB 6,662,000 for the same period in 2021, indicating an increase of 90.0%[12]. - The earnings per share attributable to the parent company for the third quarter of 2022 was RMB 0.07, up from RMB 0.04 in the same quarter of 2021[12]. - For the nine months ended September 30, 2022, the company achieved total revenue of RMB 275,659,000, a growth of 5.3% from RMB 261,737,000 in the same period of 2021[12]. - The company reported a net profit of RMB 17,377,000 for the nine months ended September 30, 2022, compared to RMB 11,829,000 for the same period in 2021, reflecting an increase of 47.2%[12]. - The total comprehensive income for the three months ended September 30, 2022, was RMB 12,645,000, compared to RMB 6,638,000 for the same period in 2021[15]. Research and Development - Research and development expenses for the third quarter of 2022 were RMB 11,220,000, compared to RMB 9,962,000 in the same quarter of 2021, indicating a rise of 12.6%[12]. - The company aims to enhance product quality and develop new testing projects in line with industry technological advancements[37]. - The company's R&D investment for the first three quarters was over RMB 18.66 million, resulting in four patent grants during the reporting period[38]. Market Presence and Strategy - The company continues to focus on the research, development, production, and distribution of in vitro diagnostic reagent products, which remains its core business[19]. - The company aims to enhance its market presence and expand its product offerings in the in vitro diagnostics sector[19]. - The company reported a slight increase in revenue and profit compared to the same period last year due to participation in domestic pandemic prevention-related business[37]. - The company has achieved approximately 70% domestic substitution in biochemical diagnostic reagents, with the market size expected to reach RMB 11 billion[35]. - The company plans to optimize supplier relationships and direct procurement to continuously reduce raw material and overall costs[36]. Shareholder Information - The company's basic earnings per share for the nine months ended September 30, 2022, was calculated based on a weighted average of 144,707,176 shares, with no adjustments for potential diluted shares[27]. - As of September 30, 2022, Mr. Wu Lebin holds 3,500,878 shares, representing 4.35% of the company's domestic shares and 2.42% of the total registered capital[41]. - Beijing Puxai Asset Management Co., Ltd. directly holds 31,308,576 shares, accounting for 38.93% of the domestic shares and 21.64% of the total registered capital[44]. - Yunnan Shengneng Investment Partnership holds 10,939,314 domestic shares and 6,780,000 H shares, representing 13.60% and 10.55% of the respective categories[44]. Corporate Governance - The board of directors recommended not to distribute an interim dividend for the nine months ended September 30, 2022[30]. - The company's total reserves as of September 30, 2022, amounted to RMB 210,451,000, reflecting an increase from RMB 185,158,000 as of September 30, 2021[29]. - The Audit Committee, consisting of three independent non-executive directors, has reviewed the unaudited condensed consolidated financial statements for the period[58]. - The company has complied with all provisions of the GEM Listing Rules Appendix 15 Corporate Governance Code as of September 30, 2022, except for the provision D.2.5[59]. - The company has decided not to establish an internal audit department due to its scale and simple operational structure, but has implemented measures to fulfill internal audit functions[60]. - The board has engaged external consultants to conduct internal reviews as determined by the audit committee[60]. - The company believes that its existing organizational structure and close supervision by management ensure adequate risk management and internal control[60]. - The board will periodically review the necessity of establishing an internal audit function and may establish an internal audit team if needed[60]. Securities Transactions - The company has not purchased, sold, or redeemed any of its listed securities during the nine months ending September 30, 2022[54].